Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy to magnetic resonance imaging with subsequent MRI-guided biopsy in biopsy-naïve patients

Castellucci, Roberto; Quevedo, Ana I Linares; Gómez, Francisco J Sánchez; Rodríguez, Jesús; Cogorno, Leopoldo; Acuña, Isidro Cogollos; Beliz, Isabel Salmeron; Legaria, Marta Muñoz Fernández de; Piñeiro, Luis Martínez

doi:10.23736/s0393-2249.17.02845-4

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the index lesion was defined as the lesion with the largest volume at pathology (12). As far as mpMRI detection of high GS tumor, literature data confirm that MRI is accurate in the identification of high Gleason pattern PCa (8)(9)(23)(24).…”

Section: Discussionmentioning

confidence: 64%

Comparing Image-guided targeted Biopsies to Radical Prostatectomy Specimens for Accurate Characterization of the Index Tumor in Prostate Cancer

Porpiglia

Luca

Checcucci

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 64%

Comparing Image-guided targeted Biopsies to Radical Prostatectomy Specimens for Accurate Characterization of the Index Tumor in Prostate Cancer

Porpiglia

Luca

Checcucci

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A change has been made to the target population definition as follows: "Patients with an elevated risk of csPCa (defined as International -In total, 16 cohort studies and the two RCTs mentioned above presented detection rates comparing mpMRI-TB to TRUS-SB. 7,9,11,12,14,16,[22][23][24][31][32][33]40,[42][43][44] Estimates for csPCa showed increased detection favoring mpMRI-TB by 3% (95% CI 0-7, p=0.03).…”

Section: Main Comments Responsesmentioning

confidence: 96%

“…Twenty-three trials (all full-text publications) compared mpMRI with a reference standard (n=5, all cohort studies) or with TRUS-SB (n=18: 2 randomized controlled trials [RCTs] and 16 cohort studies) for biopsy-naive men. The certainty of the aggregate study evidence for each comparison showed 14 of the 21 cohort studies to be at either low 6,32,40 or moderate 7,9,11,2,14,16,18,22,25,33,44 risk of bias based on a GRADE approach. 48 One of the RCTs was assessed to be at low risks of bias 20 and the other was assessed at being at unclear risk.…”

Section: Key Evidence For Recommendationmentioning

confidence: 99%

“…40 Overall estimates for the studies comparing mpMRI-TB plus TRUS-SB to targeted biopsy alone showed 6% increased csPCa detection when combining the systematic and targeted biopsy (95% CI 4-8, p<0.00001) and 8% increased detection of cis-PCa (95% CI 6-10, p<0.00001). 9,11,12,14,16,[31][32][33]39,40,[42][43][44] Justification for recommendation 1…”

Section: Main Comments Responsesmentioning

confidence: 99%

See 1 more Smart Citation

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline

Brown

Haider²,

Chin³

et al. 2022

CUAJ

View full text Add to dashboard Cite

Introduction: This clinical practice guideline is based on a systematic review to assess the use of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis of clinically significant prostate cancer (csPCa) for biopsy-naive men and men with a prior negative transrectal ultrasound-guided systematic biopsy (TRUS-SB) at elevated risk. Methods: The methods of the clinical practice guideline included searches to September of 2020 of MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. Internal and external reviews were conducted. Results: The recommendations are: Recommendation 1: For biopsy-naive patients at elevated risk of csPCa, mpMRI is recommended prior to biopsy in patients who are candidates for curative management with suspected clinically localized prostate cancer. - If the mpMRI is positive, mpMRI-targeted biopsy (TB) and TRUS-SB should be performed together to maximize detection of csPCa. - If the mpMRI is negative, consider forgoing any biopsy after discussion of the risks and benefits with the patient as part of shared decision-making and ongoing followup. Recommendation 2: In patients who had a prior negative TRUSSB and demonstrate a high risk of having csPCa in whom curative management is being considered: - mpMRI should be performed. - If the mpMRI is positive, targeted biopsy should be performed. Concomitant TRUS-SB can be considered depending on the patient’s risk profile and time since prior TRUS-SB biopsy. - If the mpMRI is negative, consider forgoing a TRUS-SB only after discussion of the risks and benefits with the patient as part of shared decision-making and ongoing followup. Recommendation 3: mpMRI should be performed and interpreted in compliance with the current Prostate Imaging Reporting & Data System (PI-RADS) guidelines.

show abstract

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer

Drost

Osses

Nieboer

et al. 2019

Cochrane Database of Systematic Reviews

385

422

View full text Add to dashboard Cite

show abstract

Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy to magnetic resonance imaging with subsequent MRI-guided biopsy in biopsy-naïve patients

Cited by 6 publications

References 0 publications

Comparing Image-guided targeted Biopsies to Radical Prostatectomy Specimens for Accurate Characterization of the Index Tumor in Prostate Cancer

Comparing Image-guided targeted Biopsies to Radical Prostatectomy Specimens for Accurate Characterization of the Index Tumor in Prostate Cancer

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer

Contact Info

Product

Resources

About